CLAIMS

1. A compound(s) or its pharmaceutically-acceptable salt(s) as shown by Formula (II),



(II)

R_3 is selected from the group consisting of 5-membered aromatic heterocycles, $C_{6\sim12}$ aryl groups and $C_{5\sim12}$ heteroaromatic rings, wherein R_3 is optionally substituted with from 1 to 3 R_{01} groups;
L_2 is independently selected respectively from the group consisting of



;

m_1 and m_2 are independently selected respectively from the group consisting of 1 and 2;
X_1 and X_2 are independently selected from the group consisting of -C(R_{d1})(R_{d2})-, -N(R_{d4})-, -O- and -S-;
R_4 is selected from the group consisting of 5-14-membered heterocycloalkyl, aryl, heteroaryl, and biaryl groups; wherein R_4 is substituted with R_{01};
R_{d1}, R_{d2}, R_{d4}, and R_{d5} are independently selected respectively from the group consisting of H, F, Cl, Br, I, CN, OH, SH, NH_2, CHO and COOH;
R_{01} is selected from the group consisting of H, F, Cl, Br, I, CN, OH, SH, NH_2, CHO, COOH and R_{02};
R_{02} is selected from the group consisting of $C_{1\text{-}10}$ alkyl groups,$C_{1\text{-}10}$ alkylamino groups, N,N-($C_{1\text{-}10}$ alkyl) amino groups, $C_{1\text{-}10}$ alkoxy groups, $C_{1\text{-}10}$ alkanoyl groups, $C_{1\text{-}10}$ alkoxycarbonyl groups, $C_{1\text{-}10}$ alkylsulfonyl groups, $C_{1\text{-}10}$ alkylsulfinyl groups, $C_{3\text{-}10}$ cycloalkyl groups, $C_{3\text{-}10}$ cycloalkylamino groups, $C_{3\text{-}10}$ heterocyclic alkyl amino groups, $C_{3\text{-}10}$ cycloalkoxy groups, $C_{3\text{-}10}$ cycloalkyl acyl groups, $C_{3\text{-}10}$ cycloalkoxy-carbonyl groups, $C_{3\text{-}10}$ cycloalkylsulfonyl groups, $C_{3\text{-}10}$ cycloalkylsulfinyl groups, C_3H_7-O-N=, CH_3-O-N=, C_2H_5-O-N=, C_2H_5-O-N=CH-, C_3H_5-CH_2-O-N=CH- and C_3H_7-O-N=CH-;
R_{02} is optionally substituted by 1 to 3 R_{001} groups;
R_{001} is selected from the group consisting of F, Cl, Br, I, CN, OH, N(CH_3)$_2$, NH(CH_3), NH_2, CHO, COOH, trifluoromethyl group, aminomethyl group, hydroxymethyl group, methyl group, methoxy group, formyl group, methoxycarbonyl group, methylsulfonyl group and methylsulfinyl group;
optionally, R_{d1} and R_{d2} interconnect together to form a 3 or 4-membered carbocyclic or heterocyclic ring.

2. The compound(s) or its pharmaceutically-acceptable salt(s) according to claim 1, wherein Formula (II) is further defined as follows:



R_{01}, R_{d1} and R_{d2} are defined as in claim 1.

3. The compound(s) or its pharmaceutically-acceptable salt(s) according to claim 1, wherein Formula (II) is further defined as follows:



R_{d1} and R_{d2} are defined as in claim 1.

4. The compound(s) or its pharmaceutically-acceptable salt(s) according to claim 1, wherein Formula (II) is further defined as follows:



wherein R_{01} is selected from the group consisting of -H, CH_3, CH_3CONH-, NH_2, $HOCH_2CH_2NH$- and CH_3NH-;
R_{04} is selected from the group consisting of C_2H_5-O-N=CH-, C_3H_5-CH_2-O-N=CH- and C_3H_7-O-N=CH-.

5. The compound(s) or its pharmaceutically-acceptable salt(s) according to claim 1, wherein Formula (II) is further defined as follows:



wherein R_{01} is selected from the group consisting of H, NH_2-, $HOCH_2CH_2NH$- and CH_3NH-;
R_{05} is selected from the group consisting of C_3H_7-O-N=, CH_3-O-N= and C_2H_5-O-N=.

6. The compound(s) or its pharmaceutically-acceptable salt(s) according to claim 1, wherein Formula (II) is further defined as follows:



wherein R_{05} is selected from the group consisting of CH_3-, C_2H_5-, C_3H_7-; and
R_{d1} and R_{d2} are defined as in claim 1.

7. The compound(s) or its pharmaceutically-acceptable salt(s) according to claim 1, wherein Formula (II) is selected from the group consisting of the following:


,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

.



,



,



,



,



,



,


,

,

,

,

,

,


,


and


.